IT House reported on February 18 that the U.S. Food and Drug Administration (FDA) has approved the first iOS and Android mobile app capable of controlling users' insulin pumps.
The app, called T:connect, works in conjunction with Tandem Diabetes Care, Inc's t:slim X2 insulin pump. The FDA-approved version allows users to easily program and cancel embolized insulin requests from their compatible smartphones.
The t:connect app previously allowed users to view their insulin pump information on their iPhone. The app shows glucose trends, pump status changes, and insulin therapy data over the past 24 hours.
The t:connect app requires iOS 14 or later and is currently compatible with the t:slim X2 insulin pump.
Users curious about Tandem's diabetes system can download the t:simulator app, which allows users to try tandem's t:slim X2 insulin pump's touchscreen interface and preview the features of the t:connect companion app.
Encyclopedia knowledge:
The insulin pump consists of a pump, a small syringe and an infusion tube connected to it. Small syringes can hold up to 3 ml of insulin, after the syringe is loaded into the pump, the guide needle at the front of the connected infusion tube is inserted into the patient's skin with a needle injector (usually the abdominal wall), and then the spiral motor of the battery-driven insulin pump pushes the piston of the small syringe, and the basic purpose of insulin infusion into the body is to simulate the secretion function of the pancreas, and the insulin is continuously injected into the user's skin according to the dose required by the human body, keeping the blood glucose stable throughout the day to achieve the purpose of controlling diabetes.